Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11818265 | 0.86 | SLC6A2 (0.38) | SMN1; SMN2CHRM5CHRM3SIGMAR1SLC6A2 | |
| SCHEMBL9541995 | 0.82 | SLC29A1 (0.31) | — | |
| SCHEMBL9541993 | 0.80 | SLC29A1 (0.33) | — | |
| SCHEMBL7307461 | 0.78 | SMN1; SMN2 (0.37) | SMN1; SMN2CHRM5CHRM3SIGMAR1SLC6A2 | |
| SCHEMBL8039857 | 0.78 | SMN1; SMN2 (0.37) | SMN1; SMN2CHRM5CHRM3SIGMAR1SLC6A2 | |
| SCHEMBL6305624 | 0.77 | — | — | |
| SCHEMBL11362056 | 0.77 | ALDH1A1 (0.38) | SMN1; SMN2 | |
| SCHEMBL14142190 | 0.74 | SMN1; SMN2 (0.35) | SMN1; SMN2CHRM5CHRM3SLC6A2SLC6A4 | |
| SCHEMBL7110339 | 0.74 | CHRM5 (0.38) | SMN1; SMN2CHRM5CHRM3SIGMAR1SLC6A2 | |
| SCHEMBL14142349 | 0.73 | SMN1; SMN2 (0.34) | SMN1; SMN2SLC6A2SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102216279-A | Phenyl pyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof | TOPHARMAN SHANGHAI CO LTD | 2011-10-12 | — | — | CN | claimed |
| US-20090156802-A1 | Quetiapine Hemifumarate Purification by Crystallization | FERMION OY (FI) | 2009-06-18 | — | — | US | claimed |
| EP-1948628-A1 | QUETIAPINE HEMIFUMARATE PURIFICATION BY CRYSTALLIZATION | Fermion Oy (FI) | 2008-07-30 | — | — | EP | claimed |
| WO-2007048870-A1 | QUETIAPINE HEMIFUMARATE PURIFICATION BY CRYSTALLIZATION | FERMION OY (FI) | 2007-05-03 | — | — | WO | claimed |
| US-20060063927-A1 | Processes for preparing quetiapine and salts thereof | CHEMAGIS LTD. (IL) | 2006-03-23 | — | — | US | claimed |
| CN-114181172-B | Efficient preparation method of quetiapine fumarate | 浙江苏泊尔制药有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-114181172-A | Efficient preparation method of quetiapine fumarate | 浙江苏泊尔制药有限公司 | 2022-03-15 | — | — | CN | disclosed |
| EP-2960907-B1 | METHOD FOR REMOVING RADIOACTIVE CESIUM, HYDROPHILIC RESIN COMPOSITION FOR REMOVAL OF RADIOACTIVE CESIUM, METHOD FOR REMOVING RADIOACTIVE IODINE AND RADIOACTIVE CESIUM, AND HYDROPHILIC RESIN COMPOSITION FOR REMOVAL OF RADIOACTIVE IODINE AND RADIOACTIVE CESIUM | DAINICHISEIKA COLOR CHEM (JP) | 2018-12-12 | — | — | EP | disclosed |
| US-10008300-B2 | Method for eliminating radioactive iodine and hydrophilic resin for eliminating radioactive iodine | DAINICHISEIKA COLOR & CHEMICALS MFG. CO. LTD. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20180151264-A1 | METHOD FOR ELIMINATING RADIOACTIVE IODINE AND HYDROPHILIC RESIN FOR ELIMINATING RADIOACTIVE IODINE | UKIMA CHEMICALS & COLOR MFG. CO., LTD. (JP) | 2018-05-31 | — | — | US | disclosed |
| EP-2806426-B1 | METHOD FOR REMOVING RADIOACTIVE CESIUM, HYDROPHILIC RESIN COMPOSITION FOR REMOVING RADIOACTIVE CESIUM, METHOD FOR REMOVING RADIOACTIVE IODINE AND RADIOACTIVE CESIUM, AND HYDROPHILIC RESIN COMPOSITION FOR REMOVING RADIOACTIVE IODINE AND RADIOACTIVE CESIUM | DAINICHISEIKA COLOR CHEM (JP) | 2018-04-25 | — | — | EP | disclosed |
| EP-2772921-B1 | METHOD FOR ELIMINATING RADIOACTIVE IODINE AND USE OF A HYDROPHILIC RESIN FOR ELIMINATING RADIOACTIVE IODINE | DAINICHISEIKA COLOR CHEM (JP) | 2017-07-05 | — | — | EP | disclosed |
| WO-1995029152-A1 | BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-11-02 | — | — | WO | disclosed |
| EP-0625997-A1 | DIAMINOCARBONATE COMPOUNDS AND THEIR USE AS CATALYSTS. | RWE DEA AG (DE) | 1994-11-30 | — | — | EP | disclosed |
| WO-1993016124-A1 | DIAMINOCARBONATE COMPOUNDS AND THEIR USE AS CATALYSTS | RWE-DEA Aktiengesellschaft für Mineraloel und Chemie (DE) | 1993-08-19 | — | — | WO | disclosed |
| EP-0240228-B1 | THIAZEPINE COMPOUNDS | ICI AMERICAS INC. (US) | 1990-11-07 | — | — | EP | disclosed |
| US-4879288-A | Novel dibenzothiazepine antipsychotic | ICI AMERICAS INC. (US) | 1989-11-07 | — | — | US | disclosed |
| US-4849422-A | PIPERAZINE-SUBSTITUTED, ANTITUSSIVE | DOMPE' FARMACEUTICI S.P.A. (IT) | 1989-07-18 | — | — | US | disclosed |
| EP-0240228-A1 | Thiazepine compounds | ICI AMERICAS INC. (US) | 1987-10-07 | — | — | EP | disclosed |
| EP-0230402-A2 | Pharmacologically active alkylol derivatives | DOMPE' FARMACEUTICI S.p.A. (IT) | 1987-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063927-A1 | Processes for preparing quetiapine and salts thereof | CYP3A5, QDPR, CYP4Z1 | SMN1; SMN2 4650/4885CHRM5 684/4885CHRM3 1938/4885 |
| US-20090156802-A1 | Quetiapine Hemifumarate Purification by Crystallization | FH, FAH, FBP1 | SMN1; SMN2 4368/4885CHRM5 3813/4885CHRM3 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.